Gold (Au) complexes attained an exceptional reach as new metal‐based anticancer agents in recent years. The FDA‐approved Au
I
complex auranofin [(2,3,4,6‐tetra‐
O
‐acetyl‐1‐thio‐β‐
d
‐glucopyranose (triethylphosphoranylidene)gold(I)] displays efficacious chemotherapeutic potential in phase I and II clinical trials for both liquid and solid tumors. Ignited by the success of auranofin as an anticancer agent, new designs and synthetic processes toward Au
I
and Au
III
complexes for unique biomedical applications are actively ongoing. In the past few years, Au
III
complexes have become attractive as premised on promising antitumor preclinical studies despite bottlenecks associated with stability and biological target identification. Advancement of gold complexes to the clinic will require agents with improved anticancer potency, unambiguous biological target, pharmacokinetic profile, and optimal stability. Thus, ligand tuning and innovative synthetic chemistry coupled with rigorous biological characterization are crucial. In this article, an overview of known synthetic strategies for the synthesis of gold anticancer complexes is presented. Primary focus on the synthesis of Au
I
and Au
III
complexes along with anticancer outcomes is outlined. This article presents medicinal inorganic chemists with an armory of synthetic tools and purification protocols to readily access highly potent gold anticancer agents.